According to Zacks, “AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The company’s pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. AIkido Pharma Inc., formerly known as Spherix Incorporated, is based in New York. “
AIkido Pharma stock opened at $0.36 on Tuesday. AIkido Pharma has a fifty-two week low of $0.30 and a fifty-two week high of $1.21. The stock has a market cap of $31.73 million, a PE ratio of -8.88 and a beta of 1.55. The firm’s 50-day simple moving average is $0.40 and its 200 day simple moving average is $0.47.
About AIkido Pharma (Get Rating)
AIkido Pharma Inc, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
- Get a free copy of the StockNews.com research report on AIkido Pharma (AIKI)
- It’s Time For FuboTV to Stand Out in the Sea of Streaming
- 3M Stock is Worth a Look Because of the Company it Keeps
- Landstar Systems Stock Can Bottom Down Here
- 3 Attractive Mid Cap Swing Trades
- Institutional Support For Rockwell International Begins To Erode
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AIkido Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIkido Pharma and related companies with MarketBeat.com's FREE daily email newsletter.